Logotipo del repositorio
Logotipo del repositorio
 

Laboratory tests for antiphospholipid syndrome diagnosis in pregnant women

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorGiraldo Calderón, Luisa Fernanda
dc.contributor.authorHenao Henao, Madeleine
dc.contributor.authorGómez Rave, Lyz Jenny
dc.contributor.authorSierra Castrillo, Jhoalmis
dc.contributor.authorMuñoz Bravo, Adriana Ximena
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2023-08-17T13:14:19Z
dc.date.available2023-08-17T13:14:19Z
dc.date.issued2022
dc.description.abstractAntiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of autoantibodies against proteins bound to negatively charged phospholipids. Obstetric antiphospholipid syndrome (APS) is characterized as an acquired autoimmune disorder associated with different obstetric complications, defined as a state of hypercoagulability, which causes a wide range of complications associated with placental insufficiency including recurrent gestational loss, fetal death, preeclampsia, preterm delivery, among others. Its diagnosis is based on the Sidney criteria which include adverse obstetric history such as: (i) three consecutive miscarriages and spontaneous abortions prior to 10 weeks gestation (ii) fetal loss on one or more occasions at 10 weeks gestation and (iii) fetal death or preterm delivery due to eclampsia or severe preeclampsia or placental insufficiency prior to 34 weeks gestation, and laboratory findings such as (i) two positive tests for lupus anticoagulant (LA) at least 12 weeks apart (ii) two positive results for acL IgG or IgM at least 12 weeks apart and (iii) two positive results for 2GPI IgG or IgM at least 12 weeks apart. The laboratory tests give rise to an antibody profile related to the risk of complications; thus establishing as a high-risk profile, the presence of AL accompanied or not by high titers for acL or aβ2GPI. On the other hand, it is important to perform a differential diagnosis with other thrombotic microangiopathies with implications in pregnancy and to rule out the presence of different entities that may course with production of antiphospholipid antibodies. Based on these aspects and the severity of the syndrome under study, articles are required to determine the importance of the laboratory tests used for the diagnosis of antiphospholipid syndrome in pregnant women.eng
dc.description.abstractEl síndrome antifosfolípido (SAF) es una enfermedad autoinmune que se caracteriza por la presencia de autoanticuerpos contra proteínas unidas a fosfolípidos de carga negativa. El síndrome antifosfolípido obstétrico (SAFO), se caracteriza por ser una alteración autoinmune adquirida asociada con diferentes complicaciones obstétricas, definiéndose como un estado de hipercoagulabilidad; que provoca una amplia gama de complicaciones que se asocian con insuficiencia placentaria incluyendo, pérdida gestacional recurrente, muerte fetal, preeclampsia, partos prematuros, entre otros. Su diagnóstico se basa en los criterios de Sidney los cuales incluyen antecedentes obstétricos adversos como: (i) tres abortos consecutivos y espontáneos previos a la semana 10 de gestación (ii) perdida fetal en una o más ocasiones a las 10 semanas de gestación y (iii) muerte fetal o parto prematuro por eclampsia o preeclampsia grave o por insuficiencia placentaria antes de las 34 semanas de gestación y resultados de laboratorio como (i) dos pruebas positivas para anticoagulante lúpico (AL) con al menos 12 semanas de diferencia (ii) dos resultados positivos para acL IgG o IgM con al menos 12 semanas de diferencia y (iii) dos resultados positivos para 2GPI IgG o IgM con 12 semanas de diferencia como mínimo. Las pruebas de laboratorio dan origen a un perfil de anticuerpos relacionado con el riesgo de complicaciones; estableciendo de esta manera como un perfil de alto riesgo, la presencia de AL acompañado o no de títulos altos para acL o aβ2GPI. Por otro lado, es importante realizar un diagnóstico diferencial con otras microangiopatías trombóticas con implicaciones en el embarazo y descartar la presencia de diferentes entidades que puedan cursar con producción de anticuerpos antifosfolípidos. Partiendo de estos aspectos y de la gravedad del síndrome en estudio se requiere de artículos que determinen la importancia de las pruebas de laboratorio utilizadas para el diagnóstico del síndrome antifosfolípidos en mujeres embarazadas.spa
dc.format.mimetypepdfspa
dc.identifier.citationLuisa Fernanda Giraldo Calderón, Madeleine Henao Henao, Lyz Jenny Gómez Rave, Jhoalmis Sierra Castrillo, Adriana Ximena Muñoz Bravo, & Valmore Bermúdez. (2022). Laboratory tests for antiphospholipid syndrome diagnosis in pregnant women. https://doi.org/10.5281/zenodo.7415369eng
dc.identifier.doihttps://doi.org/10.5281/zenodo.7415369
dc.identifier.issn26107996
dc.identifier.urihttps://hdl.handle.net/20.500.12442/13151
dc.language.isoengspa
dc.publisherSociedad Latinoamericana de Hipertensiónspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceRevista Latinoamericana de Hipertensiónspa
dc.sourceVol. 17 - Nº 6 (2022)
dc.subjectAntibodieseng
dc.subjectPregnancyeng
dc.subjectThrombosiseng
dc.subjectDiagnosiseng
dc.subjectAntiphospholipid syndromeeng
dc.subjectAnticuerposeng
dc.subjectEmbarazospa
dc.subjectTrombosisspa
dc.subjectDiagnósticospa
dc.subjectSíndrome antifosfolípidospa
dc.titleLaboratory tests for antiphospholipid syndrome diagnosis in pregnant womeneng
dc.title.translatedPruebas de laboratorio empleadas para el diagnóstico del síndrome antifosfolípidos durante la gestaciónspa
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesCervera R. Therapeutic strategies in antiphospholipid syndrome. Reumatología Clínica. 2010;6(1):37-42. DOI:10.1016/j.reuma. 2008.11.020eng
dcterms.referencesEsteve-Valverde E, Ferrer-Oliveras R, Alijotas-Reig J. Obstetric antiphospholipid syndrome. Spanish Clinical Journal. 2016;216(3):135-45. DOI:10.1016/j.rce.2015.09.003eng
dcterms.referencesSilver RM. Catastrophic antiphospholipid syndrome and pregnancy. Seminars in Perinatology. 2018;42(1):26-32. DOI:10.1080/14767058 .2017.1422715eng
dcterms.referencesArdila-Suarez O, Gómez-Puerta JA, Khamashta MA. Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies. Medicina Clínica (Spanish Edition). 2016;146(12):555-60.eng
dcterms.referencesAbrahams VM, Chamley LW, Salmon JE. Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation. Arthritis and Rheumatology. 2017;69(9):1710- 21. DOI:10.1002/art.40136eng
dcterms.referencesRestrepo Ocampo C, Arango Gutiérrez L, Rodríguez Padilla LM, Mesa Navas MA, Velásquez Franco CJ, Gutiérrez Marín JH, et al. Clinical manifestations and maternal and perinatal outcomes in pregnant women with obstetric antiphospholipid syndrome at a high complexity institution: Descriptive study. Revista Colombiana de Reumatología (English Edition). 2020;27(2):73-9. DOI:10.1016/j.rcreue.2020.06.003eng
dcterms.referencesTsikouras P, Deftereou T, Anthoulaki X, Bothou A, Chalkidou A, Christoforidou A, et al. Thrombophilia and Pregnancy: Diagnosis and Management. In: Embolic Diseases - Evolving Diagnostic and Management Approaches. IntechOpen; 2020. DOI:10.5772/intechopen.85005eng
dcterms.referencesGalarza-Maldonado C, Kourilovitch MR, Pérez-Fernández OM, Gaybor M, Cordero C, Cabrera S, et al. Obstetric antiphospholipid syndrome. Autoimmunity Reviews. 2012;11(4):288-95. DOI:10.1016/j. autrev.2011.10.006eng
dcterms.referencesAhluwalia J, Sreedharanunni S. The Laboratory Diagnosis of Antiphospholipid Syndrome. Indian Journal of Hematology and Blood Transfusion. 2017;33(1):8-14. DOI:10.1007/s12288-016-0739-yeng
dcterms.referencesChaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Frontiers in Immunology. 2019;10. DOI:10.3389/fimmu.2019.00449eng
dcterms.referencesTedesco F, Borghi MO, Gerosa M, Chighizola CB, Macor P, Lonati PA, et al. Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Frontiers in Immunology. 2018;9. DOI:0.3389/fimmu.2018.01388eng
dcterms.referencesEsteve-Valverde E, Ferrer-Oliveras R, Alijotas-Reig J. Obstetric antiphospholipid syndrome. Spanish Clinical Journal. 2016;216(3):135-45. DOI:10.1016/j.rce.2015.09.003spa
dcterms.referencesArslan E, Branch DW. Antiphospholipid syndrome: Diagnosis and management in the obstetric patient. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020;64:31-40. DOI:10.1016/j.bpobgyn. 2019.10.001eng
dcterms.referencesGuibert Toledano Z, Reyes Llerena A, Rigñack Ramírez L, Acosta Lopera D, Salgado Galloso S. Pregnancy and puerperium in systemic lupus erythematosus.Update. Cuban Journal of Rheumatology. 2013;15(2).eng
dcterms.referencesKovács M, Hartwig M, Aleksza M, Tihanyi M, Nagy T, Vajda G, et al. Antiphospholipid antibodies in relation to sterility/infertility. Human Immunology. 2012;73(7):726-31. DOI:10.1016/j.humimm.2012.04.003eng
dcterms.referencesTufano A, Coppola A, Maruotti GM, Martinelli P, Cerbone AM, di Minno G. HELLP syndrome and its relation with the antiphospholipid syndrome. Blood Transfusion. 2014;12(1):114-8. DOI: 10.2450/2013.0154-13.eng
dcterms.referencesNassar A, Uthman I, Eid J, Khamashta M. Treatment of Pregnancy Complications in Antiphospholipid Syndrome. In 2017;78(2):257-79. DOI:10.1136/annrheumdis-2018-213846eng
dcterms.referencesLlerena GAR, Guibert M, Álvarez Villanueva RR, Jesús Núñez Hernández N, Raúl I v, Prieto V. Obstetrical antiphospholipid antibody syndrome in a case series in Cuba [Internet]. Vol. 42, Cuban Journal of Obstetrics and Gynecology. 2016eng
dcterms.referencesGarcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. 2013. DOI:10.1182/blood-2013-04-496257.eng
dcterms.referencesVandevelde A, Devreese KMJ. Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. Journal of Clinical Medicine [Internet]. 2022;11(8):2164. DOI:10.3390/jcm11082164eng
dcterms.referencesDevreese KMJ, Zuily S, Meroni PL. Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of Translational Autoimmunity. 2021;4:100134. DOI:10.1016/j.jtauto.2021.100134eng
dcterms.referencesEscobar Martinez M. Antiphospholipid syndrome: generalities and diagnosis. Medicina y Laboratorio. 2013;19(11).eng
dcterms.referencesHeikal N, Martins TB, White SK, Willis R, Ware Branch D, Schmidt RL, et al. Laboratory Evaluation of Antiphospholipid Syndrome. American Journal of Clinical Pathology. 2019;15. DOI:10.1093/ajcp/aqz085.eng
dcterms.referencesMontaruli B, de Luna E, Erroi L, Marchese C, Mengozzi G, Napoli P, et al. Analytical and clinical comparison of different immunoassay systems for the detection of antiphospholipid antibodies. International Journal of Laboratory Hematology. 2016;38(2):172-82. DOI:10.1111/ ijlh.12466eng
dcterms.referencesDevreese KMJ, Zuily S, Meroni PL. Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of Translational Autoimmunity. 2021;4:100134. DOI: 10.1016/j.jtauto.2021.100134eng
dcterms.referencesBenítez Cabrera A. Determination of antiphospholipid antibodies and their relationship to thrombosis in patients with Antiphospholipid Syndrome. [Morelia]: Universidad Michoacana de San Nicolás de Hidalgo; 2016eng
dcterms.referencesPouymiró Pubillones P, Pouymiró Brooks Y, Pouymiró Brooks I. Antiphospholipid antibody syndrome. MEDISAN. 2012;16(3):429eng
dcterms.referencesPires da Rosa G, Bettencourt P, Rodríguez-Pintó I, Cervera R, Espinosa G. “Non-criteria” antiphospholipid syndrome: A nomenclature proposal. Autoimmunity Reviews. 2020;19(12):102689. DOI:10.1016/j. autrev.2020.102689eng
dcterms.referencesAlijotas-Reig J, Esteve-Valverde E, Anunciación-Llunell A, Marques- Soares J, Pardos-Gea J, Miró-Mur F. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. Journal of Clinical Medicine. 2022;11(3):675.DOI: 10.3390/ jcm11030675eng
dcterms.referencesSammaritano LR. Antiphospholipid syndrome. Best Practice & Research Clinical Rheumatology. 2020;34(1):101463. DOI:10.1016/j. berh.2019.101463eng
dcterms.referencesSammaritano LR. Antiphospholipid syndrome. Best Practice & Research Clinical Rheumatology. 2020;34(1):101463. DOI:10.1016/j. berh.2019.101463eng
dcterms.referencesGarcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. New England Journal of Medicine. 2018;378(21):2010–eng
dcterms.referencesHabe K, Wada H, Matsumoto T, Ohishi K, Ikejiri M, Matsubara K, et al. Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases. International Journal of Hematology. 2013;97(3):345-50. DOI:10.2169/internalmedicine.55.5536Detailseng
dcterms.referencesCousins L, Pericleous C, Khamashta M, Bertolaccini ML, Ioannou Y, Giles I, et al. Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2015;74(1):317-9. DOI:10.1136/annrheumdis-2014-206483eng
dcterms.referencesCamarena Cabrera DMA, Rodriguez-Jaimes C, Acevedo-Gallegos S, Gallardo-Gaona JM, Velazquez-Torres B, Ramírez-Calvo JA. Controversies Concerning the Antiphospholipid Syndrome in Obstetrics. Reumatología Clínica (Spanish Edition). 2017;13(1):30-6. DOI:10.1016/j. reumae.2016.04.005 Full text access.eng
dcterms.referencesRodríguez Pérez L, Castillo González D, Cabrera Payne Y, Tejeda González M. Antiphospholipid syndrome in women with recurrent pregnancy loss: laboratory diagnosis. Rev Cubana Hematol Inmunol Hemoter. 2015;31(4).eng
dcterms.referencesSilver RM. Catastrophic antiphospholipid syndrome and pregnancy. Seminars in Perinatology. 2018;42(1):26-32. DOI:10.1053/j.semperi. 2017.11.006eng
dcterms.referencesde Carolis S, Tabacco S, Rizzo F, Giannini A, Botta A, Salvi S, et al. Antiphospholipid syndrome: An update on risk factors for pregnancy outcome. Autoimmunity Reviews. 2018;17(10):956-66. DOI:10.1016/j. autrev.2018.03.018eng
dcterms.referencesLeal D, Zubiaurre V, Danza Á, Stevenazzi M. Obstetric antiphospholipid syndrome. Uruguayan Journal of Internal Medicine. 2021;06(02).eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
06_2022_GC_ART_Laboratory test.pdf
Tamaño:
242.09 KB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca